Skip to content
2000
Volume 28, Issue 17
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Monocyte chemoattractant protein-1 induced protein 1 (MCPIP1), one of the MCPIP family members, is characterized by the presence of both C-x8-C-x5-C-x3-H (CCCH)- type zinc finger and PilT-N-terminal domains. As a potent regulator of innate immunity, MCPIP1 exerts anti-inflammatory effects through its ribonuclease (RNase) and deubiquitinating enzyme activities to degrade cytokine mRNAs and inhibit nuclear factor- kappa B (NF-ΚB), respectively. MCPIP1 is expressed not only in immune cells but also in many other cell types, including cardiomyocytes, vascular endothelial cells (ECs) and smooth muscle cells (SMCs). Increasing evidence indicates that MCPIP1 plays a role in the regulation of cardiac functions and is involved in the processes of vascular diseases, such as ischemia-reperfusion (I/R) and atherosclerosis. To better understand the emerging roles of MCPIP1 in the cardiovascular system, we reviewed the current literature with respect to MCPIP1 functions and discussed its association with the pathogenesis of cardiovascular diseases and the implication as a therapeutic target.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867327999201113100918
2021-05-01
2025-05-07
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867327999201113100918
Loading

  • Article Type:
    Review Article
Keyword(s): atherosclerosis; cardiovascular diseases; inflammation; MCPIP1; miRNA; NF-ΚB; Ribonuclease
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test